There are currently 872 clinical trials in Phoenix, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Phoenix Children's Hospital, GSK Investigational Site, Mayo Clinic Arizona and Mayo Clinic. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263
Recruiting
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 a... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Barrow Neurological Institute /ID# 241812, Phoenix, Arizona
Conditions: Chronic Migraine
Register for Updates
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: B-Cell Acute Lymphoblastic Leukemia
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: CVC Cardiovascular Consultants, Phoenix, Arizona
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05999799
Recruiting
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: GSK Investigational Site, Phoenix, Arizona
Conditions: Dermatitis, Atopic
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: Banner Good Samaritan, Phoenix, Arizona
Conditions: Aortic Stenosis
Register for Updates
Arizona Alzheimer's Disease Research Center (ADRC)
NCT05405075
Recruiting
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigation... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
06/10/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona
Conditions: Alzheimer Disease
Register for Updates
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572
Recruiting
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971
Recruiting
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +1 locations
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346
Recruiting
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/10/2024
Locations: Mayo Clinic, Phoenix, Arizona
Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Register for Updates
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis
NCT05070858
Recruiting
The primary objective is: To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG) The secondary objectives of the study are: To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on: Clinician-assessed signs of myasthenia gravis (MG) and muscle strength Daily functioning that is impacted by signs and symptoms in patients with symptomati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: HonorHealth Neurology, Phoenix, Arizona
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191
Recruiting
The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Arizona Oncology Associates ., Phoenix, Arizona
Conditions: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Register for Updates